SHANGHAI, China — Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration (TFDA) for the treatment of primary immunoglobulin A...
Latest News
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each worth $5,000, to cover a winning applicant’s...
Cambridge, MA – A surprising MIT study published in Nature at the end of 2016 helped to spur interest in the possibility that light flickering at the frequency of a particular gamma-band brain rhythm could produce meaningful therapeutic effects for people with Alzheimer’s disease. In a new review paper in the Journal of Internal...
Cambridge, UK – Pseudomonas aeruginosa – an environmental bacteria that can cause devastating multidrug-resistant infections, particularly in people with underlying lung conditions – evolved rapidly and then spread globally over the last 200 years, probably driven by changes in human behaviour, a new study has found. P. aeruginosa is responsible...
Budapest – Recent research suggests that the emergence of tuberculosis infection in human populations dates back tens of thousands of years earlier than previously known cases in the Middle East. In collaboration with an international research team, Hungarian researchers have edited and published a special issue of the journal Tuberculosis....
Fort Lauderdale, Florida – A new research perspective entitled, “Evolving insights in blood-based liquid biopsies for prostate cancer interrogation.” was published in Oncoscience. During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths...
EVOTEC AND CHINOOK THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL PRECISION MEDICINES FOR CHRONIC KIDNEY DISEASES COLLABORATION WILL LEVERAGE THE NURTURE PATIENT BIOBANK AND EVOTEC’S MULTI-OMICS PLATFORMS PANHUNTER AND PANOMICS EVOTEC AND CHINOOK AIM TO CHARACTERISE MOLECULAR DRIVERS, IDENTIFY AND VALIDATE NOVEL TARGETS AND DRIVE PATIENT STRATIFICATION...
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited (“Kazia”, ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive...
FIRST DOSE OF EVT894, A MONOCLONAL ANTIBODY AGAINST CHIKUNGUNYA VIRUS ADMINISTERED TO A HEALTHY PARTICIPANT IN A PHASE I STUDY DEVELOPMENT OF EVT894 BY EVOTEC TOGETHER WITH ITS PARTNERS NIAID AND DUKE CLINICAL RESEARCH INSTITUTE ADDRESSING UNMET MEDICAL NEEDS IN GLOBAL HEALTH Hamburg, Germany, 28 January 2021: Evotec SE (Frankfurt...
OXFORD, United Kingdom — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will present data at two upcoming international conferences: the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 16-20, 2023, in Los Angeles, and the International Society for Extracellular Vesicles (ISEV) Annual...